Article
Oncology
Javier Garcia-Sanchez, Mayra Alejandra Mafla-Espana, Maria Dolores Torregrosa, Omar Cauli
Summary: This study aimed to investigate the effects of AROi treatment on cognitive function, depressive symptoms, and sleep quality in postmenopausal women. The results showed that AROi treatment did not significantly worsen cognitive function after 6 months and 12 months, but there were significant increases in depressive symptoms and sleep disturbances.
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Rebecca Pedersini, Pierluigi di Mauro, Vito Amoroso, Vincenza Castronovo, Manuel Zamparini, Sara Monteverdi, Lara Laini, Greta Schivardi, Deborah Cosentini, Salvatore Grisanti, Sara Marelli, Luigi Ferini Strambi, Alfredo Berruti
Summary: The use of aromatase inhibitors (AIs) as adjuvant therapy for early breast cancer does not affect insomnia, anxiety, or depression. However, it significantly decreases quality of life and increases the frequency and severity of restless legs syndrome (RLS). Patients with RLS may benefit from additional psychological support.
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Sara Caceres, Beatriz Monsalve, Angela Alonso-Diez, Belen Crespo, Maria Jose Illera, Paloma Jimena de Andres, Gema Silvan, Juan Carlos Illera
Summary: Through experimental studies on canine and human inflammatory breast cancer, it was found that anti-aromatase and anti-sulfatase therapies have inhibitory effects on tumors in vitro, while anti-sulfatase can increase tumor progression; letrozole effectively reduces tumor progression by decreasing estrogen levels.
Article
Radiology, Nuclear Medicine & Medical Imaging
Su Hyun Lee, Myoung-jin Jang, Heera Yoen, Youkyoung Lee, Yeon Soo Kim, Ah Reum Park, Su Min Ha, Soo-Yeon Kim, Jung Min Chang, Nariya Cho, Woo Kyung Moon
Summary: Background parenchymal enhancement (BPE) at surveillance breast MRI is associated with future second breast cancer risk in women with a personal history of breast cancer.
Review
Medicine, General & Internal
Kamila Boszkiewicz, Agnieszka Piwowar, Pawel Petryszyn
Summary: Aromatase inhibitors (AIs) are commonly used as first-line therapy for hormone-dependent breast cancer patients. However, their use is associated with increased risk of cardiovascular events and the development of insulin resistance and diabetes. This meta-analysis found that AIs are associated with a higher risk of cardiovascular events compared to tamoxifen (TAM), but no significant association was found with hypertension, dyslipidemia, hyperglycemia, or weight gain.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Jing Xu, Bo Cao, Chunyu Li, Guohui Li
Summary: Breast cancer is a global health concern. Endocrine therapy is crucial in treating estrogen-positive breast cancer, but it often leads to osteoporosis-related adverse events. These events increase the risk of fractures and reduce the patients' quality of life. This review explores the possibility of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer treatment and discusses the mechanisms involved and the potential of drug therapies and combinations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Molly B. Moravek, Rafael Confino, Angela K. Lawson, Kristin N. Smith, Ralph R. Kazer, Susan C. Klock, William J. Gradishar, Jacqueline S. Jeruss, Mary Ellen Pavone
Summary: The study compared recurrence and survival in breast cancer patients who pursued fertility preservation (FP) and those who did not, finding that regardless of receptor status, patients undergoing FP had similar outcomes. Age and parity were the main factors influencing the likelihood of pursuing FP, and breast cancer stage had minimal impact on this decision.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Chemistry, Medicinal
Amit Kumar Jana, Jyotsana Singh, Asha Ganesher, Amit Kumar, Arpita Banerjee, Deepak Kumar, Sarvesh Kumar Verma, Ashok Kumar Sharma, Rabi Sankar Bhatta, Rituraj Konwar, Gautam Panda
Summary: A new chemical entity, benzoxazine, was designed for improving anti-breast cancer activity. Compound 13d, as a lead compound, induced apoptosis, cell cycle arrest, and loss of mitochondrial membrane potential in breast cancer cells. In a rat syngenic mammary tumor model, both 13d and 13d-f showed significant tumor regression without causing any mortality.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Medicine, General & Internal
Milana A. Bergamino, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang
Summary: This study aimed to identify biomarkers for the response of ER+/HER2+ breast cancers to AI treatment. The results showed that HER2-E is a standardized biomarker associated with poor response to AI and worse prognosis in ER+/HER2+ breast cancers. HRD, TP53 mutational score, and immune-tumor tolerance are predictive biomarkers for poor response to AI. Additionally, new molecular subtypes identify non-HER2-E tumors that do not respond to AI and have an increased risk of relapse.
Review
Oncology
Li Huifang, Gao Jie, Feng Yi
Summary: Aromatase inhibitors are the most commonly used endocrine therapy for breast cancer patients, but they often cause adverse reactions such as muscle and joint pain, fatigue, anxiety, depression, and sleep disturbances. The rapid decline of hormones leads to inflammation and bone loss. Therefore, studying poor adherence from the perspective of neuro-immuno-endocrine is of great significance for clinical intervention.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Silvia Riondino, Vincenzo Formica, Elena Valenzi, Cristina Morelli, Valeria Flaminio, Ilaria Portarena, Francesco Torino, Mario Roselli
Summary: This study aimed to identify a cut-off point of body mass index (BMI) that would have a significant prognostic impact on stage I-II BC patients receiving AI treatment. The results showed that a BMI cut-off >29 was associated with a deteriorating disease-free survival (DFS) in AI-treated BC patients, indicating that obesity is a risk factor for recurrence in breast cancer.
Article
Oncology
Heather Greenlee, Carlos Iribarren, Jamal S. Rana, Richard Cheng, Mai Nguyen-Huynh, Eileen Rillamas-Sun, Zaixing Shi, Cecile A. Laurent, Valerie S. Lee, Janise M. Roh, Margarita Santiago-Torres, Hanjie Shen, Dawn L. Hershman, Lawrence H. Kushi, Romain Neugebauer, Marilyn L. Kwan
Summary: This study found that women with breast cancer had significantly increased incidence of cardiovascular disease events, CVD-related mortality, and all-cause mortality compared with women without breast cancer, with risks varying according to the history of cancer treatment received. Studies are needed to determine optimal care for women who have received breast cancer treatment to improve cardiovascular outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)